CEBPA and acute myeloid leukemia: The WHO does not consider necessary to formally require a minimum percentage of blasts to establish the diagnosis of AML subcategory with defining genetic abnormalities, except in two subtypes: AML with BCR::ABL1 and AML with CEBPA (although it is said to be essential the increase in “peripheral blood and/or bone marrow blasts”) (Table 1).